BC Week In Review | Feb 9, 2015
Company News

InSite, Nicox deal

InSite granted Nicox exclusive rights to develop, manufacture and commercialize AzaSite , BromSite and AzaSite Xtra in Europe, the Middle East and Africa. Nicox expects to submit MAAs for AzaSite and BromSite in 1Q16 and launch...
BC Week In Review | Sep 8, 2014
Company News

InSite, Inspire deal

In June, Akorn Inc. (NASDAQ:AKRX, Lake Forest, Ill.) paid InSite $6 million in exchange for a lower royalty rate that it pays InSite on net sales of ophthalmic product AzaSite azithromycin in North America. Last...
BC Week In Review | Jun 16, 2014
Company News

InSite, Senju deal

InSite granted Senju an exclusive, Japanese license to develop and commercialize InSite's azithromycin ophthalmic solutions using DuraSite sustained drug delivery technology, including macrolide antibiotics AzaSite 1% azithromycin and AzaSite Xtra 2% azithromycin ( ISV-405 ). AzaSite...
BC Week In Review | Jul 1, 2013
Company News

InSite, Merck deal

InSite regained North American development rights to AzaSite Xtra 2% azithromycin ophthalmic solution from Inspire Pharmaceuticals Inc. , which Merck acquired in 2011. A joint development committee between InSite and Merck will oversee development and regulatory...
BioCentury | Mar 3, 2008

Ebb & Flow

Ophthalmology company InSite Vision managed to get its non-dilutive financing done last week, but it will pay a pretty penny: the interest rate on the $60 million non-convertible note deal is 16%. Chairman, President and...
BC Extra | Feb 26, 2008
Financial News

InSite raises $60M in note deal

InSite (AMEX:ISV) raised $60 million in a private placement of non-convertible promissory notes due 2019. The notes, which bear 16% interest, are secured by royalties to be paid from U.S. and Canadian sales of AzaSite...
Items per page:
1 - 6 of 6